HIV elsewhere in the body

Besides the central nervous system and genital tract , other HIV reservoirs include certain immune cells other than CD4 T-cells, the lymph nodes, the thymus and lymphoid tissue in the gut. Anti-HIV drugs vary in their capacity to reduce viral replication in these locations.

Effective combination antiretroviral therapy appears to reduce the amount of HIV in the lymph nodes.1 But the virus often remains detectable in lymph node tissue despite prolonged suppression of blood viral load. In the Merck 035 study, which looked at combination therapy with indinavir, patients with sustained undetectable blood viral load for two years did not show evolution of HIV RNA sequences in their lymph nodes, suggesting that viral replication was minimised even though HIV was not eliminated completely.2

HIV is also found in the ocular fluid of the eye. Although not all antiretroviral drugs penetrate well into the eye, a small study of patients with ocular manifestations of AIDS-defining illnesses found that most had undetectable HIV in their aqueous humour (fluid in the front of the eyeball) within four to eight months of starting highly active antiretroviral therapy (HAART).3

More recently, researchers demonstrated that HIV continues to replicate in lymphoid tissue in the gut despite antiretroviral therapy that effectively suppresses viral load in the blood.4 They also found that patients who had been infected with HIV longer and had more inflammation were less likely to achieve viral suppression in the gut.

The difficulty in eliminating HIV from lymph tissues and other ‘sanctuary sites’ represents the main barrier to full eradication. For further information, see Can HIV be eradicated?

References

  1. Ruiz L et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 13: F1-F8, 1999
  2. Gunthard H et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 73: 9404-9412, 1999
  3. Hsu S et al. The HIV RNA levels of plasma and ocular fluids in AIDS patients with ophthalmic infections. Ophthalmologica 218: 328-332, 2004
  4. Guadalupe M et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infectred patients initiating therapy during primary or chronic infection. Journal of Virology 80: 8236-8247, 2006
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.